semaglutide
Ozempic (semaglutide) is a GLP-1 receptor agonist from Novo Nordisk for adults with type 2 diabetes. Alongside diet and exercise it improves blood sugar control, reduces major cardiovascular events in people with established cardiovascular disease, and protects kidney function in chronic kidney disease.
This page is based on FDA prescribing information and the EMA medicine record for semaglutide, cross-checked with MedlinePlus and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
After a meal the gut sends a hormone note saying food has arrived. In type 2 diabetes that note gets ignored and blood sugar climbs. Semaglutide is a long-lasting copy of the note that the body cannot quickly shred. The pancreas releases insulin on time, the liver stops dumping sugar, food leaves the stomach more slowly, and the brain feels fuller, so blood sugar settles and weight tends to fall.
In simple terms
Semaglutide belongs to the incretin mimetic class. It mimics the gut hormone GLP-1, which is normally released after meals. By activating GLP-1 receptors it helps the pancreas release the right amount of insulin when blood sugar is high, reduces the release of glucagon, and slows the movement of food out of the stomach. In the brain the same signal suppresses appetite and lowers caloric intake. Together these effects lower blood sugar in type 2 diabetes and reduce body weight.
In depth
Semaglutide is a glucagon-like peptide-1 receptor agonist that is 94 percent homologous to human GLP-1 (7-37). Upon administration it binds to and activates the GLP-1 receptor. In pancreatic beta cells this increases glucose-dependent insulin release, and it reduces elevated glucagon secretion by inhibiting pancreatic alpha cells and slows gastric emptying, which together lower postprandial glucose. In the brain, activation of GLP-1 receptors suppresses appetite, decreasing caloric intake and body weight. GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal and plays an important role in regulating appetite and caloric intake.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How semaglutide, 94% homologous to human GLP-1, lowers blood sugar and body weight
- Semaglutide is a glucagon-like peptide-1 receptor agonist that is 94 percent homologous to human GLP-1 (7-37).
- In pancreatic beta cells this increases glucose-dependent insulin release, and it reduces elevated glucagon secretion by inhibiting pancreatic alpha cells and slows gastric emptying, which together lower postprandial glucose.
- In the brain, activation of GLP-1 receptors suppresses appetite, decreasing caloric intake and body weight.
- GLP-1 is normally secreted by L cells of the gastrointestinal mucosa in response to a meal and plays an important role in regulating appetite and caloric intake.
Target: Glucagon-like peptide-1 (GLP-1) receptor
A receptor activated after meals by the gut hormone GLP-1; stimulating it boosts glucose-dependent insulin release, suppresses glucagon, slows stomach emptying, and curbs appetite.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
- To reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease
Approved uses in United States
FDA- To control blood sugar levels in people with type 2 diabetes
- To reduce the risk of a heart attack, stroke, or death in people with heart and blood vessel disease who have type 2 diabetes or who are obese or overweight
- To assist with weight loss and maintenance in people who are obese or overweight and have at least one weight-related medical problem
Approved uses in European Union
EMA- For the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes
Official sources
The statements on this page trace back to these records.
- Ozempic (semaglutide) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: semaglutide prescribing information
U.S. Food and Drug Administration
- MedlinePlus: semaglutide
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: semaglutide
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.